NLE Reproductive Health & Family Planning — Human Sexuality & Family Planning MethodsStudy Notes

Human sexuality is a holistic aspect of health spanning the lifespan, influenced by physical, psychological, social, and cultural factors. As a nurse, you must provide patient-centered care that acknowledges and respects sexuality while maintaining a non-judgmental, professional attitude aligned with RA 9173 (Nursing Practice Law) and the NCP (Nursing Care Plan) approach. Key terminological distinctions: • **Sex** refers to biological characteristics (chromosomes, hormones, reproductive anatomy). It is a physiological category assigned at birth. • **Gender** is the socially and culturally constructed roles, identities, and expressions. It includes femininity, masculinity, and non-binary identities. • **Sexual orientation** describes the pattern of emotional, romantic, and sexual attraction (heterosexual, homosexual, bisexual, asexual). It is distinct from gender identity. • **Gender identity** is a person's internal sense of gender, which may differ from assigned sex. These distinctions are essential because they inform respectful communication, reduce stigma, and ensure that nursing interventions respect the client's identity and values—a cornerstone of ethical nursing practice under the Code of Professional Conduct for Nurses in the Philippines. The **Masters and Johnson Sexual Response Cycle** describes four phases applicable across the lifespan: 1. **Excitement (arousal) phase**: Vasocongestion increases, heart rate rises, skin flushes. Duration varies widely. 2. **Plateau phase**: Physiological changes intensify; myotonia (muscle tension) builds. Orgasm is imminent but not yet triggered. 3. **Orgasm phase**: Rhythmic muscular contractions release sexual tension. Neuromuscularly coordinated; brief (seconds to minutes). 4. **Resolution phase**: The body returns to baseline. A **refractory period** (during which re-arousal is not possible) occurs, longer in males and extending with age. In nursing practice, understanding this cycle helps you recognize how illness, medications (e.g., antidepressants, antihypertensives), hormonal changes (pregnancy, menopause), and psychological factors (anxiety, depression) disrupt sexual function. The nursing diagnosis "Sexual Dysfunction" (per NANDA-I) may be applied when clients report alterations in sexual response, and counseling using the **PLISSIT Model** (Permission, Limited Information, Specific Suggestions, Intensive Therapy) offers a structured framework: • **Permission**: Normalize sexuality; open non-judgmental discussion. • **Limited Information**: Provide factual education (e.g., how medications affect arousal). • **Specific Suggestions**: Recommend strategies (e.g., alternative positions post-abdominal surgery, lubricants). • **Intensive Therapy**: Refer to a sex therapist or mental health specialist for complex issues. In the Philippine healthcare context, respect for cultural and religious values regarding sexuality is paramount. Many Filipino families maintain conservative views; nurses must balance client autonomy with family and community norms while prioritizing the individual's reproductive health rights under RA 10354. Sexuality across the lifespan is affected by: • **Pregnancy & postpartum**: Hormonal shifts, body image changes, fatigue, and fear of harming the fetus or uterus affect sexual interest and function. Counseling should normalize these changes and reassure that intercourse does not harm pregnancy (absent complications). • **Menopause & aging**: Declining oestrogen causes vaginal dryness, reduced elasticity, and slower arousal; lubrication and extended foreplay help. Erectile dysfunction in aging males often reflects vascular disease; address comorbidities and medications. • **Chronic illness & medications**: Diabetes, hypertension, depression, and cardiac disease alter sexual function. Certain drugs (SSRIs, beta-blockers, antipsychotics) reduce libido or impair orgasm; discuss alternatives with the prescriber if feasible. • **Disability**: Spinal cord injury, stroke, or amputation requires adapted counseling and positioning techniques; refer to sex therapists as needed. Nursing responsibilities in reproductive health counseling: 1. **Privacy & confidentiality**: Conduct assessments in a private setting without family present (unless the client requests otherwise). Adhere strictly to RA 10354 confidentiality requirements. 2. **Non-judgmental attitude**: Avoid moral language; use clinical, respectful terminology. Never dismiss or shame a client's sexuality or concerns. 3. **Cultural competence**: Learn about your community's values; negotiate with respect, not against the client's identity. 4. **Documentation**: Record sexuality-related assessments and counseling in the nursing notes; maintain confidentiality in all records.

Contraceptive effectiveness is the cornerstone of family planning counseling. Understanding the distinction between perfect-use and typical-use effectiveness, recognizing that user adherence often determines real-world outcomes, and presenting unbiased information are nursing imperatives under the RH Law and the Nursing Practice Law. **Defining Effectiveness:** • **Perfect use (method effectiveness)**: Effectiveness when the method is used consistently and correctly every time—a theoretical benchmark that assumes perfect adherence. • **Typical use (actual use)**: Real-world effectiveness accounting for inconsistent or incorrect use, missed doses, improper application, or other human errors. Typical-use failure is always higher than perfect-use failure. Example: Combined oral contraceptives have a **perfect-use failure rate of ~0.3% (i.e., 3 pregnancies per 1,000 women per year)**, but a **typical-use failure rate of ~7% (i.e., 70 pregnancies per 1,000 women per year)** due to missed pills, incorrect start timing, or interactions with other medications. **Long-Acting Reversible Contraceptives (LARC):** LARCs—the intrauterine device (IUD) and the subdermal implant—are the most effective reversible contraceptive methods globally and are highly recommended by the WHO and the American College of Obstetricians and Gynecologists. They achieve this by **removing day-to-day user error**; once inserted or implanted by a trained provider, the client does not need to remember to use the method daily or with every act of intercourse. LARC failure rates: • **IUD (copper or hormonal)**: ~0.2–0.8% typical-use failure (fewer than 1 pregnancy per 100 women per year). • **Subdermal implant**: ~0.05% failure (fewer than 1 pregnancy per 2,000 women per year). These compare favorably to combined pills (~7% typical-use failure), barrier methods (~18% typical-use), and natural methods (~24% typical-use failure). **Informed Choice & Voluntarism (RH Law Principles):** RA 10354 mandates that clients receive **comprehensive, unbiased information about all available methods** (natural, barrier, hormonal, IUD, and permanent surgical methods) and are empowered to choose freely without coercion, incentives, or disincentives. The nurse's role is **not to steer a client toward a particular method** but to: 1. Present the full range of options with their effectiveness, pros, cons, and risks. 2. Elicit the client's values, lifestyle, health status, and preferences. 3. Support the client's informed decision, even if it differs from the nurse's judgment or the most effective option. 4. Provide accurate use instructions and follow-up counseling. For example, a client may choose a natural method (e.g., calendar-based rhythm) for religious or philosophical reasons, despite lower typical-use effectiveness. The nurse respects this choice, provides correct teaching to optimize efficacy within that method, and ensures the client understands the higher pregnancy risk relative to LARCs or pills. **Contraceptive Counseling Framework: GATHER** The GATHER approach (widely used in Philippine health centers and endorsed by RH Law training programs) structures an effective counseling session: • **G - Greet**: Welcome the client warmly, ensure privacy, and establish rapport. Ask the client's preferred name and language. • **A - Ask**: Take a thorough reproductive and sexual history: reproductive goals (spacing vs. limiting), cycle regularity, contraceptive experience, side effects experienced with prior methods, medication use, smoking status, blood pressure, and any concerns. Screen for contraindications (e.g., history of thromboembolism, current bleeding disorders, active infection). • **T - Tell**: Present methods appropriate for the client's health status, in simple language. For example, "IUDs are among the most effective reversible methods and can be left in place for years—but require a trained provider to insert. Pills are easy to start, but you must remember to take one daily." Use visual aids (pamphlets, models, videos available at many DOH facilities). • **H - Help choose**: Facilitate the client's selection. Ask, "Which method appeals most to you?" or "What matters most—ease of use, how often you think about it, or side effects?" Guide decision-making without imposing your preference. • **E - Explain use**: Provide clear, written and verbal instructions tailored to the chosen method (see sections on specific methods below). Teach when to start, how to use correctly, what to expect, and warning signs. For pills: show how to take them, what to do if one is missed. For IUDs: explain the string check. For implants: describe the insertion procedure and what to expect (tenderness, slight bruising). • **R - Return/Refer**: Arrange a follow-up visit ~1–3 months after starting the method to assess tolerance and adherence. Address side effects; if severe, offer an alternative. Refer to a physician or specialist if complications arise (e.g., signs of infection, severe pain, suspected pregnancy). **Addressing Common Myths & Concerns:** In the Philippine context, many clients harbor misconceptions about contraception (often perpetuated by misinformation, religious teaching, or family beliefs). As a nurse, you must address these compassionately but factually: • **"Contraception causes infertility."** False. All reversible methods are immediately reversible; fertility returns quickly upon discontinuation. Even permanent methods (vasectomy, tubal ligation) do not affect the hormonal system; they simply prevent gamete transport. Counsel that planning pregnancies during peak reproductive years optimizes outcomes. • **"Hormonal contraception causes cancer."** Partially true/false. Modern low-dose pills slightly increase the risk of breast and cervical cancer but reduce the risk of ovarian and endometrial cancer. The absolute risk is low. Counsel that the benefits (preventing unintended pregnancy, which carries higher cancer risk from pregnancy complications) often outweigh risks. Screening (Pap smear, breast exam) remains important. • **"IUDs cause miscarriage or ectopic pregnancy."** False. IUDs prevent pregnancy; if pregnancy occurs (rare), it is more likely to be ectopic because tubal motility may be affected. Teach that ectopic pregnancy is a medical emergency requiring immediate care. • **"Condoms are unreliable; I should skip them."** False, but condoms are less effective than pills or IUDs with typical use (~18% typical-use failure). However, they are the **only method providing STI/HIV protection**. Counsel dual protection: condom + another method for STI prevention and pregnancy prevention. **Contraceptive Failure & Pregnancy Risk:** If a client becomes pregnant while using contraception, she requires non-judgmental, supportive care. Determine: 1. The likely conception date (when did the pregnancy begin relative to contraceptive use?). 2. Whether the method failure was user error or true method failure. 3. The client's health and pregnancy viability (via ultrasound). If the client elects to continue the pregnancy, transition to prenatal care. If she chooses abortion (where legal, such as in cases of rape, incest, or maternal health threat under Philippine law), provide supportive referral and post-abortion counseling, including contraceptive re-counseling to prevent recurrence. Document objectively and maintain confidentiality.

Natural family planning methods work by identifying the fertile window (the period during which conception is possible) and avoiding unprotected intercourse during that time. They are free, have no medical side effects, and are acceptable to clients who prefer to avoid hormones or devices for religious, philosophical, or cultural reasons. However, they require high motivation, regular and predictable menstrual cycles, accurate record-keeping, and cooperation between partners. Typical-use failure is relatively high (20–24 pregnancies per 100 women per year) due to unpredictable cycles, miscalculation, or improper use. Nurses must present these methods factually without dismissing them; they are a valid choice for informed, motivated couples. At the same time, counsel that they offer no protection against sexually transmitted infections and are less effective than hormonal or barrier methods. In the Philippine context, where Catholicism is predominant and many couples prefer natural methods, nurses must be knowledgeable and supportive. **Calendar (Rhythm) Method:** The calendar method estimates the fertile window by tracking menstrual cycle length over at least 6 consecutive cycles (preferably a full year). The formula assumes that: • Ovulation occurs ~14 days before the start of the next menstruation (relative constancy of the luteal phase). • The fertile period spans ~5 days before ovulation to 1 day after (sperm lifespan + ovum viability). **Formula:** • **Fertile window start day = (Length of shortest cycle − 18)** • **Fertile window end day = (Length of longest cycle − 11)** **Example calculation:** A woman tracks her cycles and finds the shortest is 26 days and the longest is 32 days. • Start of fertile window: 26 − 18 = day 8 • End of fertile window: 32 − 11 = day 21 • She must avoid unprotected intercourse from day 8 to day 21 of her cycle (counting day 1 as the first day of menstruation). **Nursing teaching points for calendar method:** 1. Track cycles for at least 6 months before relying on the method to ensure pattern recognition. 2. Mark the first day of each menstruation (day 1 of the cycle) clearly on a calendar. 3. Calculate the fertile window monthly using the formula above. 4. Abstain from intercourse or use a barrier method (condom) during the fertile window. 5. The method is unreliable with irregular cycles (e.g., cycles varying from 26 to 35 days); counsel that backup methods are essential. 6. Recognizes that stress, illness, or travel can shift ovulation, making the method less predictable. 7. Emphasize that both partners must agree to and comply with the abstinence schedule. **Limitations:** Calendar method is **not recommended for women with irregular cycles** or those who cannot tolerate unpredictable bleeding patterns. It is most reliable in women with cycles of 26–32 days and predictable length month-to-month. **Basal Body Temperature (BBT) Method:** The BBT method identifies ovulation by tracking the slight rise in a woman's core body temperature after ovulation. **Progesterone, secreted by the corpus luteum post-ovulation, raises the set-point of the hypothalamic thermostat by ~0.3–0.5°C (or 0.5–1°F).** This rise is sustained through the luteal phase and drops when progesterone levels fall (triggering menstruation). **Procedure:** 1. Use a **basal (resting) thermometer** (sensitive to 0.1°C increments) or a digital thermometer. 2. Take the temperature **immediately upon waking, before rising from bed**, at the same time each morning (±1 hour). Avoid eating, drinking, or moving significantly first. 3. Record the temperature daily on a BBT chart. 4. A **sustained rise of ≥0.3°C for at least 3 consecutive days** signals that ovulation has occurred. This rise marks the start of the **infertile phase**. 5. Ovulation is considered confirmed once the rise is sustained; the couple can safely resume intercourse from the third day of the temperature rise onward (or per protocol taught). **Interpretation:** • **Pre-ovulatory phase (low BBT)**: The follicular phase; temperature fluctuates slightly but remains below the baseline. • **Ovulation**: The day of LH surge (which triggers ovulation); temperature may dip slightly just before ovulation (biphasic pattern). • **Post-ovulatory phase (high BBT)**: The luteal phase; temperature rises ≥0.3°C and remains elevated, confirming ovulation has occurred. This phase is infertile. **Nursing teaching points:** 1. Emphasize that this method **detects ovulation after it has occurred**; it cannot predict ovulation in advance, so it is better used to identify the **infertile post-ovulatory phase** than to avoid the fertile window. 2. Factors that elevate BBT and can cause false readings: infection, fever, poor sleep, stress, consuming alcohol or eating before taking temperature, unusual activity. Teach that if the temperature is abnormally elevated, record it but continue tracking; the normal pattern will resume once the interference resolves. 3. Efficacy is lower if intercourse occurs before the sustained rise is confirmed; couples seeking pregnancy avoidance should abstain until 3 days of sustained rise are documented. 4. Useful in breastfeeding women or those approaching menopause (when cycles are irregular) as a secondary indicator. 5. Requires consistent record-keeping and motivation. **Advantages**: Non-invasive, free, no side effects, provides insight into one's cycle. **Disadvantages**: Retrospective (identifies ovulation after it occurs), requires consistency, affected by illness or lifestyle changes, lower typical-use effectiveness. **Cervical Mucus (Billings/Ovulation) Method:** Oestrogen causes the cervix to secrete **abundant, clear, slippery, stretchy mucus** (high spinnbarkeit and low viscosity) during the follicular phase leading up to ovulation. After ovulation, **progesterone causes the mucus to become thick, sticky, and cellular**, reducing sperm penetration. By observing mucus characteristics, a woman identifies the fertile phase. **Teaching points:** 1. **Dry days (post-ovulation to next menses)**: Minimal mucus; cervix feels dry to the touch. 2. **Sticky/tacky days (late follicular phase)**: Mucus is thick, yellow, or white; does not stretch; sticky to touch. Sperm penetration is reduced but possible. 3. **Slippery/stretchy days (peak fertile window)**: Mucus is clear, abundant, slippery, and **spinnbarkeit** (stretches between thumb and forefinger without breaking into threads). This is the **fertile phase**; ovulation is imminent. 4. **Peak day**: The last day of clear, slippery mucus—the most fertile day. It usually occurs **1–2 days before ovulation** (confirmed retrospectively by calendar or temperature rise). 5. **Post-peak days (infertile luteal phase)**: Mucus becomes thick and scant again. After 4 days of thick mucus (the "4-day rule"), pregnancy risk is minimal. **Procedure:** 1. Observe and record mucus consistency daily. Some women check by wiping toilet paper; others touch the cervix directly (if comfortable). 2. Chart observations on a Billings Method chart provided at health centers or online. 3. To avoid pregnancy: abstain or use a barrier method from the first day of stretchy mucus through 4 days after the peak day. 4. Some women notice secondary fertility signs: **Mittelschmerz (ovulation pain)**, slight rise in libido, or breast tenderness around peak mucus. **Advantages**: Free, non-invasive, women gain insight into their cycle, can be taught in a few clinic visits, effective if used correctly. **Disadvantages**: Requires observation and motivation, subjective interpretation (mucus consistency varies individually), unreliable with irregular cycles, cervicitis or sexually transmitted infections alter mucus; vaginal infections may obscure mucus observations; hormonal contraceptives, spermicides, or semen can interfere with assessment. **Symptothermal Method:** Combines **BBT, cervical mucus, and other signs** (calendar, Mittelschmerz, breast tenderness, cervical changes) to increase reliability. By cross-checking multiple indicators, a couple can identify the fertile window more accurately than any single method alone. Requires detailed charting but is significantly more effective (~1–5% failure with perfect use) than any single symptom method. **Standard Days Method (SDM):** A simplified calendar-based method designed for couples with **regular cycles of 26–32 days**. Research shows that ovulation in such cycles typically occurs between cycle days 8–19; intercourse on these days risks pregnancy. **The method:** 1. Count the first day of menstruation as day 1. 2. **Avoid unprotected intercourse on days 8–19** (the "fertile window"). 3. Days 1–7 and days 20 onward are considered infertile. 4. Many couples use **CycleBeads** (a color-coded necklace provided at health centers) to track days easily. **Advantages**: Simpler than calendar method if cycles are regular, visual aid (CycleBeads) improves adherence. **Disadvantages**: Unreliable if cycles fall outside 26–32 day range; not suitable for irregular cycles. **Lactational Amenorrhea Method (LAM):** Breastfeeding delays the return of ovulation (post-partum amenorrhea) and can suppress fertility if certain conditions are met. LAM is a temporary contraceptive method useful in the immediate postpartum period, especially in resource-limited settings where access to other methods is delayed. **Criteria for LAM efficacy (all three must be present):** 1. **Infant age <6 months old**: The method is only reliable during this window; as the baby ages and begins eating solids, fertility returns earlier. 2. **Exclusive breastfeeding**: The infant receives **only breast milk**, not formula, other liquids (water, juice), or solid foods. Any supplementation with non-breast milk feeds increases the likelihood of ovulation's return. 3. **Menses have not yet returned**: Resumption of menstruation signals return of ovulation; LAM is no longer effective. Even if menses are not present, many women ovulate before the first post-partum menstruation, so LAM alone is insufficient if pregnancy avoidance is critical (counsel backup method by 6 months or sooner if any uncertainty). **Failure of any one criterion requires a backup method** (condom, pills, or other). **Nursing teaching for postpartum clients using LAM:** 1. Emphasize that LAM is a **temporary method** valid only in the early postpartum period (~6 months maximum). 2. Counsel on the importance of **exclusive breastfeeding** (no formula, water, or foods); even occasional supplements undermine the method. 3. Teach that if menses return or if the baby is introduced to non-breast milk foods, **LAM is no longer reliable**, and another method must be started immediately. 4. Discuss what happens at 6 months: the baby will need complementary foods (solids), which will reduce breastfeeding frequency and trigger fertility's return. Plan for a more reliable contraceptive method before 6 months. 5. In Philippine healthcare, LAM is often used during the postpartum period while clients transition to a permanent method or hormonal/barrier method (notably, **progestin-only pills are safe during breastfeeding**, unlike oestrogen-containing pills). **Coitus Interruptus (Withdrawal):** Withdrawal—removing the penis from the vagina before ejaculation—is not a reliable contraceptive method and is often used without counseling. Its failures stem from: • **Pre-ejaculatory fluid (pre-cum) may contain viable sperm**, especially if the man has not urinated since the previous ejaculation. • **Timing is difficult**: even brief intravaginal ejaculation can cause pregnancy. • **No STI protection**. **Typical-use failure rate: ~22% (i.e., 22 out of 100 women per year will become pregnant).** It is significantly less effective than other methods and should not be recommended as a primary contraceptive but acknowledged as a method of last resort if nothing else is available. Counsel about more reliable alternatives and dual protection.

Hormonal contraceptives are among the most effective and widely used reversible methods globally. They work primarily by **suppressing ovulation** (preventing the LH surge that triggers release of the oocyte) and also by **thickening cervical mucus** (reducing sperm penetration) and **thinning the endometrium** (reducing potential implantation sites—though this effect is not the primary mechanism in ovulation-suppressing doses). Hormonal methods do **not** protect against sexually transmitted infections; clients at STI risk require condoms in addition. In the Philippines, oral pills and injectables are widely available through DOH health centers and private pharmacies. The nurse's role is to counsel on correct use, expected side effects, danger signs, and follow-up monitoring. **Combined Oral Contraceptives (COCs):** COCs contain **both oestrogen (usually ethinyl estradiol or estradiol valerate) and progestin** (e.g., levonorgestrel, norethisterone, desogestrel, cyproterone acetate). They are highly effective (~99% with perfect use, ~91% with typical use) when taken consistently. **Mechanism:** • Oestrogen suppresses FSH, reducing follicle recruitment. • Progestin suppresses LH, preventing the surge that triggers ovulation. • Together, they prevent ovulation in ~97% of cycles. • Secondary effects: viscous cervical mucus and thin endometrium reduce sperm transport and implantation likelihood. **Dosing & Starting:** 1. Take **one pill daily**, ideally at the same time each day (e.g., after breakfast or before bed). 2. Most commonly, pills come in a pack of **21 active pills and 7 placebo pills** (or all 28 are active in continuous-regimen formulations). With the 21/7 pack, menstruation occurs during the placebo week. 3. **Day-1 start**: Begin the first active pill on the first day of menstruation (or within 5 days); this provides immediate contraceptive cover. 4. **Sunday start or quick-start**: Alternative timing; effectiveness may be delayed, so use backup contraception (condom) for 7 days. 5. After finishing a pack, start a new one the next day (if using 21/7) or continue (if using 28-active formulation). **Missed Pills:** Consistency is paramount. Counsel clients explicitly: • **If 1 pill is missed**: Take it as soon as remembered and take the next pill at the usual time (even if this means taking 2 pills in one day). No backup is needed if she resumes on schedule. • **If 2 or more consecutive pills are missed**: Take the most recent missed pill as soon as remembered (discard any older missed pills). Resume the regular schedule. **Use a backup method (condom) for 7 days** and consider **emergency contraception** if unprotected intercourse occurred during the missed-pill window. • **If pills are missed during the first week (days 1–7) of a new pack**: There is an increased risk of ovulation, especially if the previous pack's placebo week occurred. Use backup for 7 days or consider emergency contraception if intercourse occurred. **Danger Signs (ACHES Mnemonic):** Certain symptoms suggest serious complications (venous thromboembolism, arterial thrombosis, migraine with aura). Teach clients to seek immediate medical attention if they experience: • **A - Abdominal pain (severe)**: May indicate thromboembolism, liver pathology, or GI bleeding. • **C - Chest pain or shortness of breath (dyspnea)**: Suggests pulmonary embolism or myocardial infarction. • **H - Headache (severe or persistent, different from usual)**: Especially if accompanied by visual changes, numbness, or weakness (migraine with aura or stroke). Note that migraine with aura is a **contraindication** to oestrogen-containing pills due to increased stroke risk. • **E - Eye problems (visual changes, blurring, flashing lights, or loss of vision)**: Suggests retinal vascular occlusion or other serious vascular event. • **S - Severe leg pain (calf), swelling, warmth, or redness (unilateral)**: Classic signs of deep vein thrombosis (DVT). Teach clients to seek immediate imaging and anticoagulation if suspected. Instructionalize a response: "If you experience any of these signs, **go to the nearest hospital's emergency room immediately**. Do not delay. Show the staff that you are taking contraceptive pills." **Contraindications to COCs (Current Absolute Contraindications):** 1. **History of thromboembolism or stroke** (venous or arterial). 2. **Major surgery with prolonged immobilization** planned (increase VTE risk); consider stopping pills 2 weeks before and resuming 2 weeks after mobility returns. 3. **Uncontrolled or severe hypertension** (≥160/100 mmHg); pills raise BP slightly and may precipitate cardiovascular events in hypertensive women. 4. **Current migraine with aura**: Oestrogen increases stroke risk in these women (aura suggests cortical spreading depression and underlying vascular pathology). **Progestin-only pills (POPs) are safe** for migraineurs with aura. 5. **Smoking and age ≥35 years**: Oestrogen and smoking synergistically increase thrombotic risk. Smokers ≥35 should not use COCs; recommend alternative methods or smoking cessation. 6. **Known or suspected breast cancer** (current): Hormones may stimulate growth. Some guidelines permit use after 5 years without recurrence if risks/benefits are carefully weighed; defer to oncology. 7. **Active liver disease or liver tumor**: Oestrogen is metabolized hepatically; severe disease or hepatocellular carcinoma is a contraindication. 8. **Less than 3 weeks postpartum (combined pills only)**: High VTE risk in the early postpartum period; consider progestin-only pills or barrier methods initially, then transition to COCs at 6 weeks. 9. **Currently breastfeeding (combined pills with oestrogen)**: Oestrogen reduces milk supply. **Progestin-only pills are preferred** for breastfeeding mothers. **Relative Contraindications (Use with Caution; Assess Risk/Benefit):** • History of gestational diabetes (increased risk of type 2 diabetes with hormonal methods). • Systemic lupus erythematosus with antiphospholipid antibodies (increased thrombotic risk). • Valvular heart disease with current anticoagulation. • Some medications that interact with pills (see below). **Drug Interactions:** • **Antibiotics (especially rifampicin)**: Broad-spectrum antibiotics (e.g., ampicillin, tetracyclines) may reduce enterohepatic circulation of ethinyl estradiol, lowering pill levels. Use backup contraception during the course and for 7 days after. (Rifampicin is a potent inducer; its use warrants consideration of alternative contraception.) • **Anticonvulsants (phenytoin, carbamazepine, phenobarbital)**: Increase metabolism of COCs, reducing efficacy. Consider a higher-dose COC or alternative method (LARC, injectable). • **Antiretrovirals (esp. protease inhibitors)**: Complex interactions; refer to current HIV treatment guidelines. Many experts recommend condom + additional method or LARC. • **St. John's Wort**: Herbal inducer of metabolism; reduces pill levels. Use backup or alternative method. **Side Effects (Expected & Often Transient):** Many women experience mild side effects in the first 1–3 cycles, which resolve with continued use. Counsel that these are not dangerous but warrant follow-up if bothersome: • **Nausea** (mild, usually morning; may improve by taking the pill with food or at night). • **Breast tenderness or enlargement** (oestrogen-mediated; usually mild and transient). • **Headache (mild)** (distinct from migraine or severe headache, which is a danger sign). • **Mood changes** (slight elevation or depression; rare but documented). • **Breakthrough bleeding (BTB)** (light, unpredictable vaginal bleeding outside the expected menstrual window, common in the first few packs); reassure that it is not dangerous and usually resolves. If BTB persists beyond 3 cycles, consider a higher-dose oestrogen or progestin formulation, or switch pills. • **Slight weight gain or fluid retention** (usually <2 kg; relate to sodium/fluid retention, not fat). • **Reduced libido** (rare, more common with progestin-dominant pills). **Benefits Beyond Contraception:** • **Lighter, more regular, predictable menses**: Most women experience shorter, lighter periods (flow reduced by ~40% on average). Some women and their partners appreciate this; explain that it is a safety benefit (fewer days at risk for breakthrough bleeding). • **Reduced dysmenorrhea** (painful periods) due to lower prostaglandin levels in the reduced-flow menstruation. • **Improved acne and reduced hirsutism** (especially with progestin-dominant formulations with anti-androgenic effects, e.g., cyproterone acetate). • **Reduced risk of ovarian and endometrial cancer** (by suppressing ovulation and endometrial proliferation); the reduction persists for years after discontinuation. • **Reduction in benign breast disease and ovarian cysts**. • **Improved bone density in post-menopausal women using hormone therapy** (HT), though this is distinct from contraceptive use. **Progestin-Only Pills (POPs, "Minipill"):** POPs contain only **progestin** (no oestrogen) and are particularly useful for **breastfeeding women, those with migraine with aura, and smokers ≥35**. They work by **thickening cervical mucus** (primary effect) and **suppressing ovulation in ~60–80% of cycles**; the mechanism of action differs from COCs, requiring different counseling. **Key differences from COCs:** • **No oestrogen-related risks**: No increased thrombotic risk, safe in breastfeeding, safe in smokers, safe in migraine with aura. • **Timing is critical**: Must be taken at the **same time each day** (±3 hours), as progestin alone has a narrower window of efficacy. A missed pill requires backup contraception for 48 hours. • **Effectiveness**: ~99% perfect use, ~91% typical use (similar to COCs), but more dependent on consistent timing. • **Irregular bleeding patterns**: Spotting, irregular cycles, or amenorrhea are common; counsel clients to expect variability. • **No placebo week**: All 28 pills are active; menstruation (if occurs) is unpredictable. • **Lactational suitability**: All progestin-only pills are safe in breastfeeding; no reduction in milk supply. **Injectable Contraceptives (DMPA - Depot Medroxyprogesterone Acetate):** DMPA is a long-acting progestin injectable given **150 mg intramuscularly every 12 weeks** (every 3 months, or every ~13 weeks to allow for minor delays). It is highly effective (~99% perfect use, ~97% typical use) and widely available in Philippine health centers. **Mechanism:** DMPA suppresses FSH and LH, preventing follicle development and ovulation. It also thickens cervical mucus and alters the endometrium. **Injection technique:** 1. Administer **150 mg IM in the deltoid or gluteal muscle**. 2. **Do not massage the injection site** (massage can increase the absorption rate, shortening the duration). 3. Allow ~5 minutes post-injection for hemostasis; advise the client to rest briefly and avoid heavy arm/leg use for 24 hours (if deltoid or gluteal injection, respectively). 4. Return visits: Schedule the next injection at **12 weeks (or within 13 weeks)**. Flexibility of ±1 week is accepted; if >13 weeks, backup contraception is advised until a negative pregnancy test is confirmed. **Advantages:** • Highly effective and long-acting; clients do not need to remember daily pills. • No device insertion; office-based administration. • Menstrual bleeding often reduces or stops (amenorrhea in ~30% of users by 1 year); many women appreciate lighter/absent menses. • No oestrogen, so safe in breastfeeding and smokers. • Private; no visible indication the woman is using contraception. **Disadvantages & Side Effects:** • **Irregular bleeding** (spotting, breakthrough bleeding, amenorrhea)—the most common reason for discontinuation. Counsel that unpredictable bleeding is expected, especially in the first 3 months, and that the pattern may stabilize with continued use. • **Delayed return of fertility**: After the final injection, it may take **up to 6–12 months** for menstruation and fertility to return (compared to days for pills or hours for IUDs). Counsel couples planning pregnancy that they should switch to another method if they plan to conceive sooner. • **Reversible bone density loss**: Long-term DMPA use (>5 years) is associated with a **slight, reversible reduction in bone mineral density**, particularly in adolescents and young women whose peak bone mass is still developing. The reduction is most significant in the first 2 years and recovers upon discontinuation. **Counsel calcium-rich diet, weight-bearing exercise, and vitamin D supplementation** (especially in women with limited sun exposure or dietary calcium intake). The WHO and many guidelines suggest that DMPA is not contraindicated in adolescents, but extended use warrants alternative methods if possible. • **Weight gain**: Average ~2 kg in the first year; some women gain more. This may be related to increased appetite (progestin effect) rather than fluid retention. Counsel lifestyle modifications (diet, exercise); if weight gain is significant and concerning, consider alternative methods. • **Headaches, mood changes, breast tenderness** (similar to POPs, usually mild). • **Possible reduced efficacy with some medications**: Enzyme inducers (e.g., anticonvulsants, rifampicin) may shorten the injection interval; some experts recommend shortening the interval to 10 weeks when using these agents. **Counseling for DMPA initiation:** 1. Start within **5 days of the first day of menstruation** for immediate contraceptive protection, or any day of the cycle if the client is not at current pregnancy risk (after a negative pregnancy test). 2. If given on a non-menstrual day, use backup contraception for 7 days. 3. **Screen for contraindications**: Current pregnancy, undiagnosed vaginal bleeding, severe liver disease, or current breast cancer (relative contraindication; some experts permit use 5 years after treatment cessation if the woman is informed of theoretical risks). 4. Discuss expected bleeding patterns; many women will have amenorrhea or spotting. Reassure that this is not dangerous. 5. Emphasize the importance of returning on time for the next injection (or within 13 weeks); missing the appointment increases pregnancy risk. Provide appointment cards with the next injection date. 6. Counsel return of fertility may take several months; plan ahead if pregnancy is desired. 7. In breastfeeding women, DMPA can be initiated at **6 weeks postpartum** (after breast milk is established and the early postpartum VTE risk is past); it does not reduce milk supply. **Subdermal Implant:** A **subdermal contraceptive implant** is a single or double plastic rod (depending on the product) impregnated with progestin (e.g., etonogestrel, levonorgestrel, or other agents). It is inserted under the skin of the upper arm and provides **3–5 years of contraceptive protection**, depending on the product and the woman's body weight (higher weight may require earlier replacement). It is a **LARC** and among the most effective reversible methods. **Insertion & removal:** 1. Insertion is performed by a trained provider under local anaesthesia (1–2% lidocaine). 2. A small incision (2–3 mm) is made on the inner upper arm; the implant is placed subdermally and palpable just under the skin. 3. The insertion site is closed with a small bandage; some providers use a steri-strip or suture for a few days. Healing is rapid; the site can be washed within 24–48 hours. 4. Removal requires a small incision over the implant, gentle extraction, and closure. Local anaesthesia is again used. Removal is slightly more complex than insertion and requires trained provider expertise. **Timing of insertion:** • **During the first 5 days of menstruation**: Provides immediate contraceptive protection. • **At other times during the cycle**: Requires backup contraception (condom) for 7 days. • **Postpartum (first 21 days)**: No backup needed; beyond day 21, a 7-day backup is advised. • **Postabortion**: Within 5 days of completion (first or second trimester) or insertion provides immediate protection. **Advantages:** • Highly effective (>99%). • Long-acting (3–5 years), removing user-dependent failure. • Immediately reversible; removal restores fertility quickly. • No oestrogen; safe in breastfeeding and smokers. • No systemic hormones (progestin is delivered locally to a steady state). • Low maintenance; no need to remember to use anything. • Private; not visibly apparent to others. • Can be used in adolescents. **Disadvantages & Side Effects:** • **Insertion discomfort**: Brief, manageable with local anaesthesia. Some women experience bruising or minor bleeding at the site. • **Irregular bleeding**: Similar to DMPA (spotting, breakthrough bleeding, or amenorrhea). Counseling about bleeding pattern variability is important. • **Arm tenderness** (insertion site) for a few days to weeks. • **Removal difficulty**: If the implant is inserted deeply or incompletely mobilized, removal can be challenging and requires an experienced provider. Some women hesitate to have it removed if they fear prolonged discomfort. • **Cost**: Upfront cost is higher than pills or injectables; however, the cost per year is often lower due to the 3–5 year duration. In the Philippines, the DOH provides implants at subsidized rates at public health facilities. • **Palpability**: Some women are bothered by feeling the rod under the skin; others accept it as a marker of the method in place. **Bleeding patterns with implants:** Vary widely and unpredictably: • ~30% develop amenorrhea (absence of menses). • ~40% experience oligomenorrhea (infrequent, light bleeding). • ~20% develop frequent spotting or irregular bleeding. • A small percentage experience heavy or prolonged bleeding (rare; if this occurs, evaluate for other causes, e.g., bleeding disorder, infection). Counseling should normalize this variability and reassure that it is not a sign of pregnancy or disease. **Transdermal Patch & Vaginal Ring:** Both deliver combined hormones (oestrogen + progestin) and are as effective as COCs (~99% perfect use, ~91% typical use). They are less widely available in the Philippines than pills or injectables but may be encountered in private clinics or through family planning programs. **Transdermal patch (e.g., Ortho Evra):** • Delivers ethinyl estradiol and norelgestromin. • Applied to clean, dry skin on the abdomen, upper arm, or upper torso (not breasts). • Changed **weekly** (same day of each week). • A 4-week cycle: patch 1 (week 1), patch 2 (week 2), patch 3 (week 3), patch 4 (week 4 = placebo week with no patch). • Advantages: Weekly rather than daily dosing; reduced GI side effects (not absorbed through GI tract). • Disadvantages: Visible, possible skin irritation, detachment in some individuals, slightly higher estrogen exposure than some pills (raising potential thrombotic risk slightly). • Side effects similar to COCs (nausea, breast tenderness, headache); bleeding patterns similar. **Vaginal ring (e.g., NuvaRing):** • Releases ethinyl estradiol and etonogestrel. • Inserted into the vagina and left in place for **3 weeks**, then removed for a hormone-free week (during which withdrawal bleeding occurs). • Insertion: The ring is compressed and inserted high into the vagina, where it stays; position is not critical, as it fits snugly. • Advantages: Monthly dosing (easier to remember than daily pills), local hormonal delivery (potentially lower systemic exposure), user-controlled insertion/removal. • Disadvantages: Some women are uncomfortable inserting objects into the vagina; vaginal infections or irritation can occur; possible expulsion if straining (e.g., during bowel movement); cannot be used with certain vaginal products (e.g., spermicides, antifungal creams), though barrier contraception (condoms) can be used simultaneously. • Side effects similar to COCs. • If expelled, it can be rinsed with cool (not hot) water and reinserted; contraceptive efficacy is maintained if reinserted within 3 hours. If >3 hours have passed, backup contraception is needed for 7 days. Both the patch and ring are not routinely recommended as first-line methods in public health settings in the Philippines due to cost and limited availability, but they are options for private clients and should be briefly understood for exam purposes.

Barrier methods provide a **physical or chemical block** preventing sperm from reaching the ovum. They include condoms (male and female), diaphragms, cervical caps, and spermicides. **Male and female condoms are the only methods that provide protection against sexually transmitted infections (STIs), including HIV**—a critical teaching point for clients at STI risk. All other contraceptive methods prevent pregnancy but not STIs; thus, dual protection (a condom plus another method) is recommended for sexually active individuals outside mutually monogamous relationships. Barrier methods have moderate effectiveness (18–22% typical-use failure for male condoms alone, much lower when combined with spermicide or another method), but their STI protection makes them essential in a comprehensive contraceptive counseling approach. **Male Condom:** A latex, polyurethane, or natural rubber sheath that covers the erect penis and traps ejaculate. It is the most widely used barrier method globally and is free or subsidized at Philippine health centers and through outreach programs (as part of STI/HIV prevention efforts). **Correct use:** 1. **Timing**: Apply the condom **on an erect penis before any intravaginal contact** (pre-ejaculatory fluid may contain sperm; do not rely on withdrawal). 2. **Reservoir tip**: Leave a **½-inch (1–2 cm) air-free space at the tip** (the reservoir) to accommodate ejaculate and prevent rupture. If the condom has no pre-formed reservoir, pinch the tip while rolling it down. 3. **Unrolling**: Roll the condom down the shaft of the penis, ensuring it covers the entire erect organ. If it tears during application, discard it and use a new one. 4. **Lubrication**: Use only **water-based lubricants** (e.g., KY Jelly, glycerin-based) or non-lubricated condoms with water-based lube added. **Oil-based lubricants (petroleum jelly, coconut oil, baby oil, cooking oil) degrade latex condoms within minutes**, causing rupture and failure. Silicone-based lubes are safe with latex. 5. **During intercourse**: Ensure the condom stays in place throughout intercourse; minor slippage is common. Some couples find that the male partner checking the condom base occasionally during intercourse helps. 6. **Withdrawal**: **Hold the rim of the condom at the base while withdrawing the penis** (to prevent slippage of the condom during withdrawal, leaving it behind inside the vagina—a common error). Withdraw promptly after ejaculation while the penis is still erect. 7. **After use**: Remove the condom carefully (avoid spilling semen), wrap it in toilet paper or tissue, and discard in a bin. **Do not flush condoms** (they clog plumbing); dispose in solid waste. 8. **Single use**: Each condom is for a single act of intercourse; a new condom must be used for each act, including if there is oral or anal sex before or after vaginal intercourse. **Storage:** • Store condoms in a **cool, dry place** (not in direct sunlight, in a car dashboard, or in a wallet with body heat). • Heat degrades latex; temperature >30°C accelerates breakdown. • Do not store near sharp objects that could puncture the packet. • Check the expiration date before use; expired condoms are less reliable. **Advantages:** • No systemic side effects; no hormones. • Only method with proven STI/HIV protection. • Reversible and immediately effective. • Inexpensive or free; widely available. • Improves partner involvement in contraception. • Easy to carry discreetly. • Can be used in breastfeeding without any concern. • Some men report maintained or improved sexual satisfaction (reduced premature ejaculation). **Disadvantages:** • **Moderate efficacy**: 18% typical-use failure (vs. 2% perfect-use), largely due to inconsistent or incorrect use, breakage, or slippage. • Must be applied before intercourse; can interrupt spontaneity. • Some men report reduced sensation (though modern thin condoms minimize this). • Latex allergy (rare but significant) requires polyurethane or lambskin alternatives (though lambskin does not protect against STIs as effectively). • Requires partner cooperation and may be refused by some male partners. • Slippage and breakage are real risks if not used correctly. **Common errors (teach clients to avoid):** • Applying condom after ejaculation has begun. • Not leaving a reservoir tip. • Using oil-based lubricants. • Reusing a condom. • Storing in a hot or tight location (wallet, car). • Failing to hold the rim during withdrawal. **Female Condom:** Also called a **reality condom** or **FC condom**, it is a loose-fitting sheath that lines the vagina and is controlled entirely by the woman. It is less widely used than male condoms but offers an alternative when male partners refuse condoms or when women want contraceptive autonomy. **Design & insertion:** The female condom is a polyurethane or nitrile sheath with an inner ring at the closed end and an outer ring at the open end. The inner ring is compressed for insertion, and the outer ring remains outside the vagina, covering part of the vulva. **Procedure:** 1. **Timing**: Can be inserted up to 8 hours before intercourse (unlike male condoms, which are applied just before sex). This allows the woman to apply it in advance. 2. **Position**: The woman can be standing, squatting, or lying down. She inserts the closed end into the vagina, pushes it past the pubic bone, and lets it settle as far as it will go (it will not go as high as a diaphragm). 3. **Outer ring placement**: The outer ring should rest against the vulva, partially covering the labia majora. This positioning may feel unusual; reassure the woman. 4. **Lubrication**: Apply additional lubricant as desired; the female condom is pre-lubricated, but extra lube can enhance comfort. 5. **During intercourse**: The man inserts his penis into the opening of the outer ring. If the female condom bunches or is pushed into the vagina during intercourse, pause and reposition it. With experience, this is usually not an issue. 6. **Withdrawal & disposal**: After intercourse, the woman gently removes the female condom and disposes of it in solid waste. **Advantages:** • Offers STI/HIV protection equal to male condoms. • Controlled entirely by the woman; does not depend on male cooperation. • Can be inserted in advance, allowing for greater spontaneity in the moment. • Polyurethane/nitrile is hypoallergenic (suitable for those with latex allergy). • The outer ring may provide additional stimulation. **Disadvantages:** • **Efficacy**: ~21% typical-use failure (similar to male condoms). • Unusual sensation; some women and men find it uncomfortable or odd. • More expensive than male condoms (often not subsidized in public health settings). • Insertion may be awkward initially; requires practice. • Less widely available than male condoms; not stocked at all health facilities or pharmacies. • May bunch or be pushed out of position during intercourse. **Diaphragm & Cervical Cap:** These are shallow, dome-shaped devices that mechanically block the cervix and prevent sperm from entering. They must be used **with spermicide** for effectiveness; the spermicide provides the primary contraceptive effect (immobilizing and killing sperm), and the device holds the spermicide against the cervix. Both require fitting and prescription from a healthcare provider. **Diaphragm:** A latex or silicone dome with a flexible wire rim; available in sizes 50–95 mm (fitted by a provider based on the distance from the posterior vaginal fornix to the pubic bone). **Use:** 1. Insert **spermicide (nonoxynol-9 gel or cream) into the dome and around the rim** to coat the cervix. 2. Insert into the vagina before intercourse; the dome covers the cervix, and the rear rim rests in the posterior fornix. 3. Ensure correct placement: the device should cover the cervix completely, and you should be able to feel the cervix through the dome. 4. **Leave in place at least 6 hours after intercourse** (to allow spermicide to kill all sperm); do not remove before this time. Do not leave in longer than 24 hours (increases risk of toxic shock syndrome). 5. If intercourse occurs again, **add more spermicide to the vagina without removing the diaphragm** (the first dose of spermicide is consumed during intercourse). 6. After 24 hours, remove the diaphragm by inserting a finger under the rim and pulling downward. 7. Wash with mild soap and water, dry, and store in a cool, dry place (avoid heat and oil). **Refitting after childbirth, weight change, or pelvic surgery**: The vaginal dimensions change; refit the diaphragm within 6 weeks postpartum or if weight changes by >7 pounds, or after pelvic surgery. An ill-fitting diaphragm reduces effectiveness. **Advantages:** • Non-hormonal; no systemic side effects. • Reversible and immediately effective. • Reusable for years (with proper care). • Woman controls insertion/removal. • Can be used with other methods (e.g., condom for dual protection). • Acceptable to those avoiding hormones or devices. **Disadvantages:** • Moderate efficacy (~12% typical-use failure with spermicide alone; ~6% with diaphragm + spermicide). • Requires fitting and prescription; unavailable without healthcare provider interaction. • Spermicide must be applied each time and if intercourse is repeated. • Messy (spermicide is viscous, may leak). • Potential for allergic reaction or irritation (spermicide, latex). • **Risk of toxic shock syndrome (TSS)** if left in >24 hours (use barrier method awareness training). • Does not protect against STIs. • Requires user comfort with insertion into the vagina. **Cervical Cap:** Smaller than a diaphragm; a thimble-shaped device that fits snugly over the cervix and is held in place partly by suction. Sizes: 22, 25, 28 mm (one size usually fits most women, but fitting is still necessary). It is similar in use to the diaphragm but less commonly available in the Philippines. **Use:** • Insert spermicide into the cap's dome. • Insert high into the vagina, over the cervix, ensuring a seal is formed (test by gently pulling the cap; if suction is adequate, it resists removal). • **Leave in place 6–48 hours** after intercourse. Longer duration than the diaphragm is sometimes tolerated, but TSS risk increases, so counsel <48 hours. • If intercourse is repeated, no additional spermicide is needed (unlike the diaphragm); this is an advantage. **Advantages over diaphragm:** • Smaller; more discreet. • Does not require additional spermicide if intercourse is repeated. • Can be left in longer. **Disadvantages:** • Riskier for TSS (longer allowable duration). • Difficult fitting; not available everywhere. • Efficacy similar to diaphragm (~9–16% typical-use failure). • Does not protect against STIs. • Risk of cervical irritation or ulceration if kept in too long. **Spermicides (Nonoxynol-9, N-9):** A detergent chemical that immobilizes and kills sperm. Available as **gels, creams, foams, films, or vaginal tablets**. Used alone, spermicide has only **~28% typical-use effectiveness** and is not recommended as sole contraception. It is usually combined with a barrier method (diaphragm, cervical cap, or condom) for increased efficacy. **Use:** • Insert high into the vagina, near the cervix, before intercourse. • Effectiveness peaks ~5–30 minutes after insertion. • If intercourse is delayed >1 hour, effectiveness wanes; reapply. • If intercourse occurs again, reapply spermicide. • Do not douche or rinse the vagina before sperm has had time to reach the upper genital tract (~6 hours); this reduces efficacy. **Advantages:** • No hormones; no systemic side effects. • Available without prescription; inexpensive. • Can be combined with other methods. • Immediately reversible. **Disadvantages:** • **Low efficacy alone** (~28% typical-use failure). • Requires application before intercourse (can interrupt spontaneity). • Messy; may leak. • Frequent use may irritate vaginal/penile mucosa (vaginal irritation in ~15–20% of users; some irritation increases STI risk, particularly HIV acquisition). • Does not protect against STIs; frequent use may increase STI susceptibility. • Allergic reactions possible (rare). • **Nonoxynol-9 is microbicidal in vitro but does not protect against STIs in vivo and may increase STI transmission risk with frequent use** due to mucosal irritation. It is NOT recommended as an STI preventive. **Counsel that spermicide alone is unreliable for pregnancy prevention and should not be used as sole contraception**—especially in couples who have already completed their families or who use it inconsistently.

The intrauterine device (IUD) is a small, T-shaped device inserted into the uterine cavity by a trained healthcare provider. It is one of the most effective and most cost-effective reversible contraceptive methods and is classified as a **long-acting reversible contraceptive (LARC)**. The IUD achieves high effectiveness by **removing user-dependent failure**; once inserted, no further action is required from the user until removal is desired. The IUD is particularly valuable in the Philippines, where DOH programs promote LARCs as part of comprehensive family planning services. **Types of IUDs:** **Copper IUD (e.g., Copper T 380A, TCu-380A):** A plastic T-frame wrapped in copper wire, with copper sleeves on the arms. The copper is **spermicidal**—it immobilizes sperm, reduces sperm viability, and prevents fertilisation and implantation. Copper is also toxic to the oocyte, further preventing pregnancy. • **Duration**: Effective for **10–12 years** (Copper T 380A is approved for 12 years). The copper is gradually depleted; after this period, removal and reinsertion of a new device are recommended. • **Mechanism**: Primarily spermicidal (preventing fertilisation); also creates an inflammatory endometrial response unfavorable to implantation. • **Efficacy**: <1% failure rate (fewer than 1 pregnancy per 100 women per year); among the most effective reversible methods. • **Return to fertility**: Immediate upon removal; fertility is fully restored within the menstrual cycle. • **Effect on menstruation**: May cause heavier, longer periods with more cramping (dysmenorrhea) in the first few cycles. Some women adapt; others find it unacceptable and choose alternative methods. Over time, some women experience lighter periods again. Anticipatory guidance reduces dissatisfaction. **Levonorgestrel-releasing IUD (e.g., Mirena, Liletta, Levosert):** A plastic T-frame with a hormone reservoir that releases **levonorgestrel (a progestin)** directly into the uterus. The hormone is absorbed systemically to some degree, but the primary effect is local (endometrial suppression). • **Duration**: **3–7 years** depending on the product and dose (Mirena lasts 5 years; Liletta lasts 3 years; newer formulations may last up to 7 years). Verify the product duration in your setting. • **Mechanism**: Primarily progestin-mediated—thickens cervical mucus, suppresses ovulation (in some cycles), and atrophies the endometrium, making implantation unlikely. • **Efficacy**: <1% failure rate, similar to copper IUD. • **Return to fertility**: Immediate upon removal; ovulation typically resumes within 1–2 cycles. • **Effect on menstruation**: Typically reduces menstrual flow significantly or causes amenorrhea (absence of menses) in ~30% of users by 1 year. Many women appreciate lighter or absent menses. Breakthrough spotting may occur, especially in the first 3 months. • **Systemic hormone exposure**: Minimal, though small amounts of levonorgestrel enter systemic circulation. It is considered safe for breastfeeding mothers and those who wish to avoid systemic hormones. Some women report mood changes or breast tenderness (rare), reflecting minor systemic exposure. **IUD Insertion Procedure:** 1. **Timing**: Insert during menstruation (when the cervix is softly patent and pregnancy is unlikely) or within 5 days of the start of menses. Can also insert immediately postpartum (within 10 minutes of placental delivery) or at other times after excluding pregnancy (via history, examination, or pregnancy test). 2. **Preparation**: - Take a detailed history to exclude contraindications (see below). - Perform bimanual pelvic exam to determine uterine size, position (ante/retroversion), and patency of cervical canal. - Screen for active pelvic infection or STIs (via history; clinical signs); defer insertion if present (treat infection first). 3. **Procedure**: - Insert a speculum; visualize the cervix. - Clean the cervix and uterine canal with an antiseptic solution (povidone-iodine or chlorhexidine). - Insert a tenaculum (grasping forceps) on the anterior cervix for traction, straightening any cervical flexion. - Gently insert a uterine sound into the cavity to determine the uterine length (critical for device selection; typically 6–9 cm). Do not force the sound; if resistance is encountered, do not proceed (suspect perforation risk). - Open the IUD inserter (a sterile applicator tube containing the IUD) and introduce it through the cervix to the fundus, positioning the IUD at the top of the cavity. - Withdraw the inserter, leaving the IUD in place. - Cut the IUD strings short (leaving ~1–2 cm visible at the external cervical os) using sterile scissors or the cutting kit provided. 4. **Post-insertion**: - Explain expected vaginal spotting and cramping for a few days. - Provide antibiotic and analgesic if needed. - Schedule a follow-up visit in 4 weeks to check IUD placement (by palpating strings and confirming IUD position on ultrasound if indicated). - Teach the client to self-check the strings monthly (described below). **IUD Contraindications & Precautions:** **Absolute contraindications (do not insert IUD):** • **Active pelvic infection** or current sexually transmitted infection (STI); defer until treated. • **Unexplained vaginal bleeding**; exclude malignancy or coagulopathy first. • **Pregnancy** (known or suspected); confirm negative pregnancy test or clinical evidence. • **Anatomical abnormalities** of the uterus (e.g., uterine cavity <6 cm, severe leiomyomas, markedly distorted cavity) that prevent safe insertion or retention. • **Perforation of the uterus** during insertion (rare but is a complication); manage appropriately and counsel on an alternative method. • **Current or recent postpartum/post-abortion sepsis**; defer until resolved. • **Known or suspected copper allergy** (absolute contraindication to copper IUD; levonorgestrel IUD is safe). True copper allergy is rare; assess carefully (contact dermatitis from copper jewelry is not systemic allergy). • **Wilson's disease** (a genetic disorder of copper metabolism); avoid copper IUD. Levonorgestrel IUD can be used. **Relative contraindications (use with caution; assess risk/benefit; may require specialist input):** • **Immunosuppression** (e.g., HIV with CD4 <200, active chemotherapy, or long-term systemic corticosteroids): IUD may be safe, but expert consultation is recommended. Many authorities now permit IUD use in stable HIV. • **Valvular heart disease** without current antibiotic prophylaxis for bacteremia: Some guidelines suggest antibiotic prophylaxis during insertion, though many modern guidelines accept IUD without prophylaxis if the risk of endocarditis is low. Consult cardiology. • **History of ectopic pregnancy**: Not a contraindication; IUDs actually reduce the risk of ectopic pregnancy (by preventing pregnancy overall). If ectopic pregnancy occurs despite IUD use, it is a medical emergency. • **Heavy or prolonged menses pre-insertion**: Copper IUD may worsen bleeding (relative); consider levonorgestrel IUD instead (likely to improve bleeding). Explore alternatives with the client. **IUD Monitoring & String Checks:** After insertion, clients should: 1. **Feel for the strings**: Every month after menses, insert a clean finger into the vagina and feel for the plastic strings emerging from the cervix. The strings are thin and may be difficult to feel; it is normal if not found on every attempt. 2. **What to report** (see below: PAINS mnemonic for warning signs): - If strings are no longer palpable or become longer/shorter (possible expulsion or perforation). - Absence of a partner's ability to feel the strings (possible migration into the uterus, though rare). 3. **Routine follow-up**: Check-up at 4 weeks post-insertion, then as per program guidelines (usually annually or as needed). Ultrasound may confirm IUD position if there is concern about placement, expulsion, or perforation. **IUD Warning Signs: PAINS Mnemonic** Teach clients to seek immediate medical attention if they experience: • **P - Period late or abnormal (heavy or prolonged) bleeding**: May signal ectopic pregnancy (though rare with IUD), expulsion, or other pathology. Pregnancy risk with IUD is minimal (~1% but if it occurs, higher chance of ectopic), so a late period requires pregnancy testing. Abnormal bleeding may indicate IUD perforation, PID, or other gynecological pathology. • **A - Abdominal pain or pain with intercourse (dyspareunia)**: May signal PID, ectopic pregnancy, perforation, or expulsion. Significant pain warrants evaluation. • **I - Infection symptoms (abnormal discharge, fever, or chills)**: Suggests pelvic inflammatory disease (PID), which is a gynecological emergency. While IUD use does not significantly increase PID risk in monogamous women, clients at risk for STIs should have condom protection added. PID requires antibiotics and, in severe cases, IUD removal. • **N - Not feeling well (fever, chills, malaise) or generalized illness**: Non-specific but may accompany PID or other serious infection. Warrants evaluation. • **S - String missing, shorter, or longer**: Suggests expulsion (partial or complete), perforation with uterine fundal migration, or infection/inflammation causing the string to seem shorter. Any change in string length/presence requires evaluation (ultrasound to locate the IUD). **Management of PAINS:** Any of these signs requires:**prompt evaluation (history, examination, ultrasound if indicated)**. Do not delay care. Remove the IUD if PID is confirmed or if perforation/expulsion is diagnosed. Provide antibiotics for infection. Counsel on an alternative method after resolution. **Advantages of IUD:** • **Highest efficacy** among reversible methods (<1% failure rate). • **Long-acting** (3–12 years depending on type); no maintenance required. • **Immediately reversible**: Fertility returns within one cycle of removal. • **Non-hormonal option** (copper IUD) for those avoiding hormones; hormone-releasing option for those wanting reduced menses. • **Cost-effective**: Despite high upfront cost, cost-per-year is low due to duration; DOH subsidizes IUDs in public facilities. • **No systemic side effects** from the IUD itself (though levonorgestrel IUD releases small amounts of hormone, systemic effects are minimal). • **No drug interactions**: IUDs are unaffected by antibiotics, anticonvulsants, or other medications (unlike pills). • **Suitable for postpartum women** and breastfeeding mothers (copper IUD and levonorgestrel IUD are both safe; do not reduce milk supply). • **Suitable for adolescents and nulliparous women** (despite earlier concerns, current evidence supports IUD use in these populations). **Disadvantages & Potential Side Effects:** • **Insertion discomfort**: Variable; ranges from minimal to moderate cramping during insertion. Analgesics (ibuprofen) pre-insertion and post-insertion reduce discomfort. Local anesthesia may be offered in some settings. • **Post-insertion cramping & spotting**: Common for a few days to weeks; reassure that it is temporary. • **Irregular bleeding** (especially copper IUD): Heavier, longer, or more frequent periods in the first 3 months, then usually stabilizes. Copper IUD may increase flow by 20–30% in some women. Levonorgestrel IUD typically reduces bleeding or causes amenorrhea. • **Perforation** (rare, <1 per 1,000): Risk increases if inserted immediately postpartum or in women with uterine abnormalities. Signs include loss of strings, pelvic pain, or vaginal bleeding; ultrasound confirms. If perforation occurs, the IUD must be removed, usually by laparoscopy or laparotomy. • **Expulsion** (~2–5% in first year): Partial expulsion (with strings visible) or complete expulsion (device passes unnoticed or in menses). More common in nulliparous women and within the first 3 months. If noticed, remove the device and counsel on an alternative method or reinsertion after menses. • **Pelvic Inflammatory Disease (PID)**: IUD use does not significantly increase PID risk in women in stable, monogamous relationships, but it may increase severity if PID occurs. Women at STI risk should use condoms in addition. If PID develops, antibiotics are given, and IUD removal may be necessary. • **Strings cutting into penis or irritation during intercourse** (rare): Trim strings shorter; if discomfort persists, consider a different contraceptive. • **Ectopic pregnancy** (if pregnancy occurs with IUD in place, which is very rare): The risk of ectopic pregnancy is reduced compared to no contraception, but if contraceptive failure occurs and pregnancy is established with IUD in place, ectopic pregnancy is more likely (proportionally) than intrauterine pregnancy. Any pregnancy with an IUD is a medical emergency requiring immediate ultrasound, IUD removal if feasible, and careful monitoring. **Copper IUD as Emergency Contraception:** The copper IUD is the **most effective emergency contraceptive method**, effective up to **5 days after unprotected intercourse** (or even up to 12 days in some women). It works by preventing implantation and possibly sperm transport. **Efficacy: ~99%** (compared to ~95% for levonorgestrel emergency pills and ~89% for combined emergency pills taken within 72 hours). The copper IUD has the added benefit of providing ongoing contraception for years after insertion. For clients seeking both emergency contraception and longer-term protection, the copper IUD is an excellent choice. Counsel that insertion may be slightly more uncomfortable in the emergency setting due to cervical tightness or anxiety, but it is safe and highly effective. **IUD in Special Populations:** • **Postpartum women**: Can insert within 10 minutes of placental delivery (immediate postpartum IUD insertion, IPPI) or wait until 4 weeks postpartum (delayed insertion). IPPI carries slightly higher expulsion risk but provides earlier protection. Both timing options are safe. Breastfeeding is unaffected. • **Post-abortion women**: Insert immediately (within 5 days of complete abortion) to prevent rapid re-conception. Protects against STIs if the abortion was spontaneous; may require antibiotic prophylaxis if induced or if STI risk exists. • **Adolescents**: IUD is safe and recommended by WHO and ACOG for adolescents; dispel myths about IUDs causing infertility in young women. Nulliparous status is not a contraindication. • **HIV-positive women**: IUD is generally safe; some guidelines recommend antiretroviral therapy (ART) and CD4 >200 before insertion. Counsel dual protection (condom + IUD) to prevent STI transmission to partners. **Removal of IUD:** IUD removal is simple and can be done in a clinic setting by a trained provider: 1. Visualize the cervix with a speculum. 2. Grasp the strings with a sterile instrument (forceps or removal hook). 3. Apply gentle, steady traction, pulling downward. Slight resistance may be felt as the IUD emerges from the cervix. Do not jerk or apply excessive force (risk of uterine perforation). 4. Remove the device; inspect it for completeness. If any part remains, ultrasound or further exploration may be needed. 5. Document removal and counsel on an alternative method if ongoing contraception is desired. Fertility typically returns immediately (ovulation in the next cycle).